ATE478894T1 - Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept - Google Patents

Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept

Info

Publication number
ATE478894T1
ATE478894T1 AT05778159T AT05778159T ATE478894T1 AT E478894 T1 ATE478894 T1 AT E478894T1 AT 05778159 T AT05778159 T AT 05778159T AT 05778159 T AT05778159 T AT 05778159T AT E478894 T1 ATE478894 T1 AT E478894T1
Authority
AT
Austria
Prior art keywords
adept
beta
cea scfv
lactamase
constructs
Prior art date
Application number
AT05778159T
Other languages
English (en)
Inventor
Judith Fox
Fiona Harding
M Rashid
Volker Schellenberger
Original Assignee
Genencor Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor Int filed Critical Genencor Int
Application granted granted Critical
Publication of ATE478894T1 publication Critical patent/ATE478894T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT05778159T 2004-04-15 2005-04-12 Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept ATE478894T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56238604P 2004-04-15 2004-04-15
US63600204P 2004-12-14 2004-12-14
PCT/US2005/012270 WO2005111078A2 (en) 2004-04-15 2005-04-12 Anti-cea scfv-beta-lactamase contructs (cab molecules) in adept

Publications (1)

Publication Number Publication Date
ATE478894T1 true ATE478894T1 (de) 2010-09-15

Family

ID=35394728

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05778159T ATE478894T1 (de) 2004-04-15 2005-04-12 Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept

Country Status (7)

Country Link
US (2) US8088609B2 (de)
EP (1) EP1735350B1 (de)
JP (1) JP4699450B2 (de)
AT (1) ATE478894T1 (de)
CA (1) CA2562711C (de)
DE (1) DE602005023138D1 (de)
WO (1) WO2005111078A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3110454B1 (de) * 2014-02-24 2020-11-18 Sangamo Therapeutics, Inc. Verfahren und zusammensetzungen zur nukleasevermittelten gezielten integration
CN107164412B (zh) * 2017-06-30 2020-10-23 山东兴瑞生物科技有限公司 一种安全型抗cea嵌合抗原受体修饰t细胞的制备方法及其应用
WO2021225399A1 (ko) * 2020-05-08 2021-11-11 (주)에스엠티바이오 암 치료를 위한 키메라 항원 수용체

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4522611A (en) * 1982-12-27 1985-06-11 Esco Corporation Sprocket assembly with replaceable teeth
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
EP0196864A3 (de) 1985-03-25 1988-03-23 Cetus Corporation Behandlung und Sekretion von rekombinanten Proteinen mittels alkalischer Phosphatase, dazu verwendbare DNA-Sequenzen und mittels dieser Sequenzen transformierte Zellen
US5773435A (en) 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5081235A (en) 1989-07-26 1992-01-14 City Of Hope Chimeric anti-cea antibody
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
NZ276943A (en) 1993-11-10 1998-02-26 Schering Corp Substituted For Alpha-interferon conjugated to a non-antigenic polymer (preferably a polyalkylene oxide) and its preparation
AU719513B2 (en) * 1996-05-04 2000-05-11 Astrazeneca Ab Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20030068792A1 (en) 2000-12-14 2003-04-10 Yiyou Chen Targeted enzymes
US20030147874A1 (en) 2000-12-14 2003-08-07 Volker Schellenberger Targeted enzyme prodrug therapy
WO2002047717A2 (en) 2000-12-14 2002-06-20 Genencor International, Inc. Targeted enzyme prodrug therapy
JP4688343B2 (ja) * 2001-05-16 2011-05-25 ルネサスエレクトロニクス株式会社 強誘電体メモリ装置
US20030100467A1 (en) 2001-09-12 2003-05-29 Wolfgang Aehle Binding phenol oxidizing enzyme-peptide complexes
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
EP1511861A4 (de) 2002-06-12 2007-12-05 Genencor Int Verfahren und zusammensetzungen für die milieuabhängige bindung eines angezielten mittels an ein target
WO2005058236A2 (en) * 2003-12-12 2005-06-30 Genencor International, Inc. Cab molecules

Also Published As

Publication number Publication date
WO2005111078A9 (en) 2006-03-30
EP1735350B1 (de) 2010-08-25
EP1735350A2 (de) 2006-12-27
DE602005023138D1 (de) 2010-10-07
US20120107314A1 (en) 2012-05-03
CA2562711C (en) 2013-09-17
JP4699450B2 (ja) 2011-06-08
WO2005111078A3 (en) 2006-07-27
US8728470B2 (en) 2014-05-20
JP2008501313A (ja) 2008-01-24
US8088609B2 (en) 2012-01-03
US20080096810A1 (en) 2008-04-24
WO2005111078A2 (en) 2005-11-24
CA2562711A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
IL273422A (en) Methods and systems for extracorporeal organ treatment
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
AU305666S (en) Pet treat
LTC2100614I2 (lt) Antikūnas prieš PDGFR-alfa, skirtas naudoti auglių gydymui
CY1116261T1 (el) Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων
CA115720S (en) Lid
TW200723527A (en) Bi-directional transistor and method therefor
CA112672S (en) Cable connector
EP2244735A4 (de) Antikörpertherapie zur verwendung im verdauungstrakt
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
EA200701918A1 (ru) Белок липокалин
WO2008150530A3 (en) Cripto binding molecules
TR201909522T4 (tr) Anti-tümör aktivitesine sahip bir nonapeptit.
DE602004027992D1 (de) In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
DE102005020647A8 (de) Verbinder, Verbindersystem und Verwendung
MX2007005202A (es) Polisacaridos de estreptococo modificados y usos de los mismos.
TW200641091A (en) Organometallic complexes
ATE478894T1 (de) Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
AU306244S (en) Lotion applicator
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
WO2006116076A3 (en) Tab molecules
TR200302193T4 (tr) Kombinasyon kemoterapisi.
CA114867S (en) Apparatus for optical authentication of documents
ATE307838T1 (de) Klebstoffzubereitungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties